Companies: Making the impossible possible

Leveraging an exponential leap in biological data generation to create diverse cell types for therapeutic applications across diabetes, cancer, and immune disorders

World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Advances in sequencing and genetic medicine are making personalized healthcare inevitable; this effort aims to translate that potential into clinical reality.

Treatiung first patient with internally derived N of 1 ASO Q1 2026, additional patients expected to be treated later this year. Expanding beyond ASO to siRNA therapeutics in 2026

Unlocking the full potential of genetic medicines by developing delivery technologies that target tissues beyond the liver—enabling precise treatment of diseases in the CNS, muscle, and kidneys

Entering phase I clinical trials with macrophage targeting LNP in cancer in 2026

Pioneering lifespan extension therapeutics starting with the companion animal market—creating the scientific and regulatory foundation for translation to human health

Decoding the human epigenome—an uncharted frontier with potential to transform our understanding of health and disease—led by one of the strongest teams in the field.

Betting on a synthetic biology platform that extends protein chemistry beyond nature’s 20 amino acids, led by top academics turning their research into scalable biomanufacturing

Expand partner footprint, manufacturing capability and initiate foundational models for peptide/small protein design

Enabling precise DNA insertion into the human genome—a foundational breakthrough that could unlock new gene-editing therapies and turn the body into its own biomanufacturing system.

Nominating DC for clinical trials 2026